» Articles » PMID: 36861462

The Effectiveness of Atrial Fibrillation Identification Using Noninvasive Long-term Electrocardiographic Monitoring System (NOMED-AF TECH)

Abstract

Introduction: Although it is well‑known that longer electrocardiographic (ECG) monitoring allows for detection of paroxysmal silent atrial fibrillation (SAF), it is still unknown how long the ECG monitoring should last to increase the probability of SAF diagnosis.

Objectives: Our aim was to analyze ECG acquisition parameters and timing to detect SAF during the Noninvasive Monitoring for Early Detection of Atrial Fibrillation study.

Patients And Methods: The protocol assumed up to 30 days of ECG telemonitoring of each participant in order to reveal AF / atrial flutter (AFL) episodes lasting at least 30 seconds. SAF was defined as AF detected and confirmed by cardiologists in asymptomatic individuals. The ECG signal analysis was based on the results of 2974 participants (98.67%). AF/AFL episodes were registered and confirmed by cardiologists in 515 individuals, that is, 75.7% of all patients (n = 680) in whom AF/AFL diagnosis was established.

Results: The median monitoring time to detect the first SAF episode was 6 days (interquartile range [IQR], 1-13). Fifty percent of the patients with this type of arrhythmia were identified by 6th day (IQR, 1-13) of the monitoring, and 75% by the 13th day of the study. Paroxysmal AF was registered on average on 4th day (IQR, 1-10).

Conclusions: The ECG monitoring time to detect the first episode of SAF in at least 75% of patients at risk of this arrhythmia was 14 days. Detection of 1 patient with de novo AF, SAF, or de novo SAF, required monitoring of, respectively, 17, 11, and 23 patients.

Citing Articles

Wear Your Heart on Your Sleeve: Smart Textile ECG Wearables for Comfort, Integration, Signal Quality and Continuous Monitoring in Paroxysmal Atrial Fibrillation.

Avanu A, Dodi G Sensors (Basel). 2025; 25(3).

PMID: 39943314 PMC: 11820156. DOI: 10.3390/s25030676.


Cardiovascular Outcomes in Patients with Atrial Flutter and Oral Anticoagulation: The Predictive Role of Left Atrial Appendage Thrombus in a Long-Term, Prospective, Observational Cohort Study.

Turek L, Sadowski M, Kurzawski J, Janion M J Clin Med. 2025; 13(24.

PMID: 39768647 PMC: 11677956. DOI: 10.3390/jcm13247724.


Silent cerebral ischemic lesions in ablation-naïve patients with non-valvular atrial fibrillation: Does the pulmonary vein anatomy matter?.

Glowniak A, Drelich-Zbroja A, Tarkowski A, Marzeda P, Wojewoda K, Wysokinska K Cardiol J. 2024; 32(1):35-42.

PMID: 39589069 PMC: 11870011. DOI: 10.5603/cj.99142.


Differences in global, regional, and national time trends in disability-adjusted life years for atrial fibrillation and flutter, 1990-2019: an age-period-cohort analysis from the 2019 global burden of disease study.

Tang J, Zhang Q, Peng S, Li H, Hu W, Hao M Front Cardiovasc Med. 2024; 11:1401722.

PMID: 39267808 PMC: 11390633. DOI: 10.3389/fcvm.2024.1401722.


Elevated plasma protein carbonylation increases the risk of ischemic cerebrovascular events in patients with atrial fibrillation: association with a prothrombotic state.

Nowak K, Zabczyk M, Natorska J, Zalewski J, Undas A J Thromb Thrombolysis. 2024; 57(7):1206-1215.

PMID: 38965130 PMC: 11496363. DOI: 10.1007/s11239-024-03003-z.